Tech Recruitment Goliath to Open Its First Office in Switzerland
12.1.2021 18:00:00 EET | Business Wire | Press release
UK staffing firm Frank Recruitment Group has today announced the opening of its latest location in Geneva, Switzerland.
The new office is the cloud recruitment company's eighth in Europe, bringing its total number of global hubs to 21.
Frank Recruitment Group, founded in Newcastle upon Tyne in 2006 with just three members of staff, now employs almost 2,000 people worldwide and is part of Tenth Revolution Group, the global leader in cloud talent solutions. The Swiss location will add a number of new team members to that headcount, with plans to create up to 50 jobs within five years.
The move will see Frank Recruitment Group further increase its reach in Europe and enable the firm to better support its growing global client base.
With the country's technology market expanding fast, and digitalisation and cloud migration at the top of every Swiss CIO's agenda, demand for IT professionals to support transformation is mounting.
"Our new Swiss base will allow us to offer better support to our clients and partners in the region, at a time when specialist technology recruitment consulting is more needed than ever," said Director of Sales Paul Hanley, who will be leading the new location.
"We want to replicate the success we’ve achieved in other global regions here in Switzerland by solidifying our position as the leaders in cloud tech staffing solutions, and continue to enable digital transformation by delivering the best permanent and contract tech talent to businesses that need it," Hanley said.
"I'm especially proud to be launching our Swiss office," said Zoë Morris, Frank Recruitment Group President. "2020 was a challenging year for the staffing industry, so it feels like a special achievement to be opening a new location and growing our business at this time. We feel very privileged to be able to serve this exciting market and create new jobs in the area in the process."
Hanley added, "Our launch team is packed with seasoned, multi-lingual staffing experts, all of whom have significant experience within the Swiss recruitment industry. Our focus is entirely on the tech market, and that will allow us to deliver the kind of dedicated, specialist expertise that's been missing in the Swiss market so far. I'm incredibly excited to get to work in the market, and make a real impact for both businesses and tech professionals in the area by connecting the right people with the right jobs."
At the new location, Frank Recruitment Group will initially launch its Nigel Frank, Mason Frank, and FRG Technology Consulting brands, which recruit for Microsoft, Salesforce, and emerging technology specialists, respectively.
The Swiss office is based at 14 Rue du Rhône, Geneva.
Note to editors:
ABOUT FRANK RECRUITMENT GROUP
Frank Recruitment Group is a division of Tenth Revolution Group, the world’s leading experts in cloud talent solutions. Founded in Newcastle upon Tyne, in 2006, Frank Recruitment Group creates and delivers highly sought-after professionals in some of the industry’s most skills-scarce ecosystems.
The company employs nearly 2,000 people across 20 offices, including Dallas, New York, Philadelphia, San Francisco, Tampa, Denver, Scottsdale, Charlotte, and Irvine in the US. EMEA and APAC are served by nine offices across the UK, Germany, the Netherlands, Spain, and locations in Singapore and Australia.
The group operates seven trading brands that each focus on a specific technology product: Jefferson Frank (AWS), Nigel Frank International (Microsoft Dynamics and Azure), Mason Frank International (Salesforce), Washington Frank (enterprise ERP), Anderson Frank (NetSuite), Nelson Frank (ServiceNow), and FRG Technology Consulting (Marketing Automation and emerging technologies).
Frank Recruitment Group was named one of Europe’s fastest-growing companies and received recognition as one of the UK’s top 100 private companies with the fastest-growing profits. The group plans to expand its outreach globally and attract more trainee recruiters in strategic hubs to meet demand for its services.
For more information, visit: www.frankgroup.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005733/en/
Contact information
Media Enquiries:
Josie Middleton
T: +44 (0)191 338 7553
E: j.middleton@frankgroup.com
W: www.frankgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release
Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
